15 research outputs found

    Replication Attack Mitigations for Static and Mobile WSN

    Full text link
    Security is important for many sensor network applications. Wireless Sensor Networks (WSN) are often deployed in hostile environments as static or mobile, where an adversary can physically capture some of the nodes. once a node is captured, adversary collects all the credentials like keys and identity etc. the attacker can re-program it and replicate the node in order to eavesdrop the transmitted messages or compromise the functionality of the network. Identity theft leads to two types attack: clone and sybil. In particularly a harmful attack against sensor networks where one or more node(s) illegitimately claims an identity as replicas is known as the node replication attack. The replication attack can be exceedingly injurious to many important functions of the sensor network such as routing, resource allocation, misbehavior detection, etc. This paper analyzes the threat posed by the replication attack and several novel techniques to detect and defend against the replication attack, and analyzes their effectiveness in both static and mobile WSN.Comment: 12 page

    Caffeic Acid Phenethyl Ester Causes p21Cip1 Induction, Akt Signaling Reduction, and Growth Inhibition in PC-3 Human Prostate Cancer Cells

    Get PDF
    Caffeic acid phenethyl ester (CAPE) treatment suppressed proliferation, colony formation, and cell cycle progression in PC-3 human prostate cancer cells. CAPE decreased protein expression of cyclin D1, cyclin E, SKP2, c-Myc, Akt1, Akt2, Akt3, total Akt, mTOR, Bcl-2, Rb, as well as phosphorylation of Rb, ERK1/2, Akt, mTOR, GSK3α, GSK3β, PDK1; but increased protein expression of KLF6 and p21Cip1. Microarray analysis indicated that pathways involved in cellular movement, cell death, proliferation, and cell cycle were affected by CAPE. Co-treatment of CAPE with chemotherapeutic drugs vinblastine, paclitaxol, and estramustine indicated synergistic suppression effect. CAPE administration may serve as a potential adjuvant therapy for prostate cancer
    corecore